This article is more than 5 years old. Information may no longer be current.
Top stories in cardiology: FDA acts on anticoagulant antidote, review shows direct oral anticoagulants safe
Click Here to Manage Email Alerts
Among the top stories in cardiology last week were the FDA approving an antidote to two direct oral anticoagulants and a review showing direct oral anticoagulants were as safe and effective as warfarin.
Other popular stories include a study concluding food deserts increased risk for heart failure hospitalizations, data that showed long-term sitting affected vascular health and findings regarding carvedilol and trastuzumab’s impact on patients with nonmetastatic HER-2 positive breast cancer and weak markers of heart failure. – by Melissa J. Webb
Second-generation antidote for two direct oral anticoagulants approved
Portola Pharmaceuticals announced that the FDA approved its Prior Approval Supplement for the second generation of andexanet alfa, allowing for its broad commercial launch in the U.S. Read more.
Review: Direct oral anticoagulants as safe, effective as warfarin
Direct oral anticoagulants were similar or better in safety and efficacy vs. warfarin in patients with nonvalvular atrial fibrillation, according to a systematic review published in the Annals of Internal Medicine. Read more.
Food deserts increase risk for heart failure hospitalizations
Individuals with heart failure living in a food desert had increased risk for repeat all-cause and heart failure hospitalization, according to a study published in The American Journal of Cardiology. Read more.
Long-term sitting affects vascular health
Long bouts of uninterrupted sitting in relatively healthy patients negatively impacted markers of peripheral and central vascular health, according to a study published in The American Journal of Cardiology. Read more.
Carvedilol with breast cancer treatment reduces echocardiographic findings
Patients with nonmetastatic HER-2 positive breast cancer and weak markers of heart failure treated with trastuzumab had reductions in systolic and diastolic echocardiographic findings when concomitantly treated with carvedilol, according to findings presented at EuroEcho-Imaging. Read more.